Observe Medical Beheer

Beheer criteriumcontroles 1/4

De CEO Observe Medical's is Jorgen Mann, benoemd in Feb2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.2% van de aandelen van het bedrijf, ter waarde NOK 179.50K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.7 jaar en 4.8 jaar.

Belangrijke informatie

Jorgen Mann

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

CEO

Jorgen Mann

less than a year

Tenure

Mr. Jørgen Mann was Chief Commercial Officer of Observe Medical ASA from January 2023 until 2024 and serves as it's Interim Chief Executive Officer since February 2024. He has experience in sales and senio...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Rune Nystad	Chief Development Officer	less than a year	NOK 3.11m	0.47% NOK 348.1k
Jorgen Mann	Interim Chief Executive Officer	less than a year	geen gegevens	0.20% NOK 152.0k
Johan Fagerli	Interim Chief Financial Officer	less than a year	geen gegevens	0.10% NOK 76.2k

0.7yrs

Gemiddelde duur

Ervaren management: Het managementteam van OBSRV wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.7 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Terje Bakken	Chairman of the Board	5.3yrs	NOK 300.00k	geen gegevens
Kathrine E. Andreassen	Director	5.3yrs	NOK 225.00k	0.35% NOK 264.1k
Jan van Der Linden	Member of Advisory Board	4.8yrs	geen gegevens	geen gegevens
Anders Ternhag	Member of Advisory Board	4.8yrs	geen gegevens	geen gegevens
Eskild Endrerud	Independent Director	2.3yrs	NOK 255.00k	0.41% NOK 307.8k
Line Tonnessen	Independent Director	2.3yrs	NOK 265.00k	0.38% NOK 283.5k

4.8yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van OBSRV wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Observe Medical Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Observe Medical ASA Appoints Jørgen Mann as Permanent CEO

Observe Medical Asa Announces CFO Changes

Chief Financial Officer exercised options to buy kr149k worth of stock.

Observe Medical ASA Appoints Jørgen Mann as Chief Commercial Officer

No independent directors

Observe Medical ASA Appoints Carsten Trygve Bøgh as Chief Technology Officer, Effective 2 October 2022

Recent updates

First half 2024 earnings released: kr0.12 loss per share (vs kr0.66 loss in 1H 2023)

Observe Medical ASA Appoints Jørgen Mann as Permanent CEO

Is Observe Medical (OB:OBSRV) Using Too Much Debt?

Observe Medical Asa Announces CFO Changes

Full year 2023 earnings released: kr1.05 loss per share (vs kr1.08 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Shareholder dilution

Chief Financial Officer exercised options to buy kr149k worth of stock.

Observe Medical ASA has completed a Follow-on Equity Offering in the amount of NOK 35.670322 million.

Observe Medical ASA to Report First Half, 2024 Results on Aug 30, 2024

Observe Medical ASA (OB:OBSRV) signed a letter of intent to acquire UnoMeter portfolio of Nordic distributor Vingmed from Vingmed AS.

Observe Medical ASA has filed a Follow-on Equity Offering in the amount of NOK 55 million.

Observe Medical ASA announced that it has received NOK 7.25 million in funding

Second quarter 2023 earnings released: kr0.33 loss per share (vs kr0.15 loss in 2Q 2022)

New major risk - Share price stability

Full year 2022 earnings released: kr1.08 loss per share (vs kr1.34 loss in FY 2021)

Observe Medical ASA Appoints Jørgen Mann as Chief Commercial Officer

Observe Medical ASA to Report Fiscal Year 2022 Final Results on Apr 28, 2023

Observe Medical ASA to Report First Half, 2023 Results on Aug 25, 2023

No independent directors

Third quarter 2022 earnings released: kr0.28 loss per share (vs kr0.43 loss in 3Q 2021)

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Observe Medical ASA Appoints Carsten Trygve Bøgh as Chief Technology Officer, Effective 2 October 2022

Second quarter 2022 earnings released: kr0.15 loss per share (vs kr0.068 profit in 2Q 2021)

Is Observe Medical (OB:OBSRV) Using Debt In A Risky Way?

Observe Medical ASA Announces Executive Appointments

First quarter 2022 earnings released: kr0.46 loss per share (vs kr0.25 loss in 1Q 2021)

Observe Medical ASA to Report Q1, 2022 Results on Jun 03, 2022

No independent directors

Full year 2021 earnings released: kr1.34 loss per share (vs kr2.22 loss in FY 2020)

Observe Medical ASA Announces Executive Changes

Observe Medical ASA (OB:OBSRV) completed the acquisition of Biim Ultrasound AS.

Here's Why Observe Medical (OB:OBSRV) Can Afford Some Debt

Observe Medical ASA to Report Q4, 2022 Results on Mar 29, 2022

We Think Observe Medical (OB:OBSRV) Has A Fair Chunk Of Debt

First quarter 2021 earnings released

Nya Karolinska Sjukhuset Initiates New Studies to Broaden the Clinical Scope of Use for Sippi

Observe Medical Asa Announces an Order to Deliver Newly Introduced Blood & Fluid Warmer System, Including Disposable Supplies, to Two University Hospitals and One Regional Hospital in Nordic Market

Observe Medical (OB:OBSRV) Is Making Moderate Use Of Debt

Full year 2020 earnings released: kr1.88 loss per share (vs kr1.36 loss in FY 2019)

Observe Medical ASA announces Nya Karolinska Sjukhuset in Sweden Resumes the Implementation of Sippi® in Clinical Use At Cardiothoracic ICU Unit

New 90-day high: kr29.80

Observe Medical Asa Announces Hospital in Northern Italy Has Equipped the Icu Department with Sippi® Systems in Clinical Use

Observe Medical ASA Announces Collaborations with the Norwegian Medtech Agency and Yallow Life Science AS

New 90-day high: kr16.00

Observe Medical Receives Significant Order for Medical Consumables from A Hospital Region in the Nordic Market

Observe Medical ASA Announces Doctoral Dissertation Further Demonstrates Clinical Benefits of Sippi®

New 90-day high: kr14.70

Observe Medical ASA Appoints Anders Nachtweij as New Head of Sales

New 90-day low: kr11.40

New 90-day low: kr11.90

Observe Medical ASA (OB:OBSERV) completed the acquisition of Sylak AB from ABIGO Medical AB.

New 90-day low: kr12.00

Observe Medical ASA (OB:OBSERV) signed a non-binding term sheet Sylak AB from ABIGO Medical AB for SEK 6 million.

New 90-day low: kr13.20

Earnings released

Observe Medical ASA to Report Q1, 2021 Results on May 12, 2021

Observe Medical ASA has completed a Follow-on Equity Offering in the amount of NOK 44.999999 million.

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur